Ultragenyx Pharmaceutical (RARE) Interest & Investment Income (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) reported Interest & Investment Income of $6.0 million for Q1 2026, down 14.29% year-over-year from $7.0 million in Q1 2025, and down 7.86% on a QoQ basis from $6.5 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) has 14 years of Interest & Investment Income data on file, last reported at $6.0 million in Q1 2026.
- Quarterly Interest & Investment Income fell 14.29% year-over-year to $6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.2 million (down 31.29% YoY) and the FY2025 annual result came in at $25.0 million, down 32.43% from the prior year.
- Interest & Investment Income fell to $6.0 million in Q1 2026 per RARE's latest filing, from $6.5 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $10.7 million in Q3 2024 and bottomed at $494000.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $6.2 million (2022), against an average of $6.2 million.
- The widest annual swing landed in 2022, when Interest & Investment Income surged 1308.64%; it then sank 45.36% in 2025.
- Tracing RARE's Interest & Investment Income over 5 years: stood at $6.2 million in 2022, then soared by 43.03% to $8.9 million in 2023, then grew by 13.3% to $10.0 million in 2024, then sank by 35.17% to $6.5 million in 2025, then declined by 7.86% to $6.0 million in 2026.
- Per Business Quant, the three latest RARE Interest & Investment Income figures stand at $6.0 million (Q1 2026), $6.5 million (Q4 2025), and $5.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | 6.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.00 Mn |
| Dec 31, 2025 | 6.51 Mn |
| Sep 30, 2025 | 5.86 Mn |
| Jun 30, 2025 | 5.79 Mn |
| Mar 31, 2025 | 7.00 Mn |
| Dec 31, 2024 | 10.04 Mn |
| Sep 30, 2024 | 10.73 Mn |
| Jun 30, 2024 | 7.40 Mn |
| Mar 31, 2024 | 8.82 Mn |
| Dec 31, 2023 | 8.87 Mn |
| Sep 30, 2023 | 5.88 Mn |
| Jun 30, 2023 | 5.96 Mn |
| Mar 31, 2023 | 6.29 Mn |
| Dec 31, 2022 | 6.20 Mn |
| Sep 30, 2022 | 3.48 Mn |
| Jun 30, 2022 | 899,000.00 |
| Mar 31, 2022 | 494,000.00 |
| Dec 31, 2021 | 440,000.00 |
| Sep 30, 2021 | 408,000.00 |
| Jun 30, 2021 | 441,000.00 |
| Mar 31, 2021 | 639,000.00 |
| Dec 31, 2020 | 984,000.00 |
| Sep 30, 2020 | 1.34 Mn |
| Jun 30, 2020 | 1.80 Mn |
| Mar 31, 2020 | 2.92 Mn |
| Dec 31, 2019 | 2.77 Mn |
| Sep 30, 2019 | 3.32 Mn |
| Jun 30, 2019 | 4.06 Mn |
| Mar 31, 2019 | 3.09 Mn |
| Dec 31, 2018 | 2.63 Mn |
| Sep 30, 2018 | 2.73 Mn |
| Jun 30, 2018 | 2.45 Mn |
| Mar 31, 2018 | 1.74 Mn |
| Dec 31, 2017 | 724,000.00 |
| Sep 30, 2017 | 1.12 Mn |
| Jun 30, 2017 | 1.15 Mn |
| Mar 31, 2017 | 1.08 Mn |
| Dec 31, 2016 | 912,000.00 |
| Sep 30, 2016 | 922,000.00 |
| Jun 30, 2016 | 971,000.00 |
| Mar 31, 2016 | 984,000.00 |
| Dec 31, 2015 | 918,000.00 |
| Sep 30, 2015 | 673,000.00 |
| Jun 30, 2015 | 456,000.00 |
| Mar 31, 2015 | 273,000.00 |
| Dec 31, 2014 | 195,000.00 |
| Sep 30, 2014 | 171,000.00 |
| Jun 30, 2014 | 149,000.00 |
| Mar 31, 2014 | 93,000.00 |
| Dec 31, 2013 | 59,000.00 |
| Sep 30, 2013 | 68,000.00 |